News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Orwin John A
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/02/2023 |
4
| Orwin John A (Director) has filed a Form 4 on Seagen Inc.|
Txns:
| Granted 2,044 shares
@ $0 |
|
| 05/19/2023 |
4
| Orwin John A (Director) has filed a Form 4 on Travere Therapeutics, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Granted 13,500 options to buy
@ $17.11, valued at
$231k
|
|
| 02/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/20/2022 |
4
| Orwin John A (President & CEO) has filed a Form 4 on Atreca, Inc.|
Txns:
| Sold 20,908 shares
@ $1.7752, valued at
$37.1k
|
|
| 06/15/2022 |
4
| Orwin John A (President & CEO) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 260,000 options to buy
@ $1.845, valued at
$479.7k
Disposed/sold 260,000 options to buy
@ $13.97, valued at
$3.6M
Granted 241,000 options to buy
@ $1.845, valued at
$444.6k
Disposed/sold 241,000 options to buy
@ $22.07, valued at
$5.3M
Granted 148,754 options to buy
@ $1.845, valued at
$274.5k
Disposed/sold 148,754 options to buy
@ $10.02, valued at
$1.5M
Granted 58,995 options to buy
@ $1.845, valued at
$108.8k
Disposed/sold 58,995 options to buy
@ $10.02, valued at
$591.1k
|
|
| 05/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/28/2021 |
4
| Orwin John A (President & CEO) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 260,000 options to buy
@ $3.18, valued at
$826.8k
|
|
| 09/13/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/29/2021 |
4
| Orwin John A (President & CEO) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 260,000 options to buy
@ $13.97, valued at
$3.6M
|
|
| 05/19/2020 |
4
| Orwin John A (Director) has filed a Form 4 on Retrophin, Inc.|
Txns:
| Granted 3,000 shares
@ $0
Granted 9,000 options to buy
@ $15.43, valued at
$138.9k
|
|
| 05/19/2020 |
4
| Orwin John A (Director) has filed a Form 4 on SEATTLE GENETICS INC /WA|
Txns:
| Granted 1,335 shares
@ $0
Granted 3,171 options to buy
@ $160.33, valued at
$508.4k
|
|
| 03/19/2020 |
4
| Orwin John A (President & CEO) has filed a Form 4 on Atreca, Inc.|
Txns:
| Bought 6,000 shares
@ $12.79, valued at
$76.7k
|
|
| 02/28/2020 |
4
| Orwin John A (President & CEO) has filed a Form 4 on Atreca, Inc.|
Txns:
| Granted 241,000 options to buy
@ $22.07, valued at
$5.3M
|
|
| 07/30/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/22/2019 |
4
| Orwin John A (Director) has filed a Form 4 on SEATTLE GENETICS INC /WA|
Txns:
| Granted 2,963 shares
@ $0
Granted 7,038 options to buy
@ $64.38, valued at
$453.1k
|
|
| 05/10/2019 |
4
| Orwin John A (Director) has filed a Form 4 on Retrophin, Inc.|
Txns:
| Granted 2,000 shares
@ $0
Granted 8,000 options to buy
@ $17.94, valued at
$143.5k
|
|
| 10/29/2018 |
4
| Orwin John A (Director) has filed a Form 4 on ARRAY BIOPHARMA INC|
Txns:
| Granted 25,000 options to buy
@ $0
Granted 5,000 restricted stock units
@ $0
Exercised 5,000 restricted stock units
@ $0 |
|
| 05/22/2018 |
4
| Orwin John A (Director) has filed a Form 4 on SEATTLE GENETICS INC /WA|
Txns:
| Granted 3,700 shares
@ $0
Granted 9,260 options to buy
@ $56.77, valued at
$525.7k
|
|
| 05/11/2018 |
4
| Orwin John A (Director) has filed a Form 4 on Retrophin, Inc.|
Txns:
| Granted 2,500 shares
@ $0
Granted 10,000 options to buy
@ $26.52, valued at
$265.2k
|
|
| 10/27/2017 |
4
| Orwin John A (Director) has filed a Form 4 on ARRAY BIOPHARMA INC|
Txns:
| Exercised 5,000 shares
@ $10.47, valued at
$52.4k
Granted 25,000 options to buy
@ $10.47, valued at
$261.8k
Granted 5,000 restricted stock units
@ $0
Exercised 5,000 restricted stock units
@ $0 |
|
| 05/23/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/27/2017 |
4
| Orwin John A (Director) has filed a Form 4 on Retrophin, Inc.|
Txns:
| Granted 4,375 shares
@ $0
Granted 17,500 options to buy
@ $17.53, valued at
$306.8k
|
|
| 10/31/2016 |
4
| Orwin John A (Director) has filed a Form 4 on ARRAY BIOPHARMA INC|
Txns:
| Exercised 5,000 shares
@ $5.83, valued at
$29.2k
Granted 5,000 restricted stock units
@ $0
Granted 25,000 options to buy
@ $5.95, valued at
$148.8k
Exercised 5,000 restricted stock units
@ $0 |
|
| 09/02/2016 |
4
| Orwin John A (President & CEO) has filed a Form 4 on Relypsa Inc|
Txns:
| Granted 11,250 shares
@ $0
Unknown transaction of 10,142 shares
@ $32, valued at
$324.5k
Disposed/sold 55,000 shares
@ $32, valued at
$1.8M
Granted 45,000 options to buy
@ $18.87, valued at
$849.2k
Disposed/sold 67,500 options to buy
@ $18.87, valued at
$1.3M
Disposed/sold 727,877 options to buy
@ $7.4, valued at
$5.4M
Disposed/sold 94,500 options to buy
@ $27.21, valued at
$2.6M
Disposed/sold 105,000 options to buy
@ $28.38, valued at
$3M
|
|
| 08/17/2016 |
4
| Orwin John A (President & CEO) has filed a Form 4 on Relypsa Inc|
Txns:
| Paid exercise price by delivering 3,994 shares
@ $31.89, valued at
$127.4k
|
|
| 06/07/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 05/24/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 02/17/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 10/24/2013 |
4
| Orwin John A (Director) has filed a Form 4 on ARRAY BIOPHARMA INC|
Txns:
| Granted 25,000 options to buy
@ $5.6, valued at
$140k
|
|
| 06/28/2013 |
4
| Orwin John A (Director) has filed a Form 4 on AFFYMAX INC|
Txns:
| Paid exercise price by delivering 16,334 shares
@ $1.0225, valued at
$16.7k
Gifted 15,000 shares
@ $0 |
|
| 12/04/2012 |
4
| Orwin John A (CEO) has filed a Form 4 on AFFYMAX INC|
Txns:
| Sold 15,798 shares
@ $24.22, valued at
$382.6k
Exercised 12,498 options to buy
@ $6.9, valued at
$86.2k
Exercised 3,300 options to buy
@ $5.83, valued at
$19.2k
|
|
|
|
|